These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 10584135

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T.
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [Abstract] [Full Text] [Related]

  • 3. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
    Büntzel J, Glatzel M, Schuth J, Weinaug R, Küttner K, Fröhlich D.
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
    [Abstract] [Full Text] [Related]

  • 4. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S, Hoffmanns H.
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Amifostine--a radioprotector in locally advanced head and neck tumors.
    Schönekäs KG, Wagner W, Prott FJ.
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
    [Abstract] [Full Text] [Related]

  • 9. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL, Chao KS, Haughey B.
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [Abstract] [Full Text] [Related]

  • 10. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R.
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [Abstract] [Full Text] [Related]

  • 11. [New data on cytoprotection in radiotherapy].
    Sauer R, Strnad V.
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
    [No Abstract] [Full Text] [Related]

  • 12. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI, Chambers MS, Weber RS, Eisbruch A.
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [Abstract] [Full Text] [Related]

  • 13. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M, Rosenthal DI, Chalian AA, Lustig R, Hershock D, Miller L, Weinstein GS, Weber RS.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):72-7. PubMed ID: 15093901
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J, Rosine D.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [Abstract] [Full Text] [Related]

  • 17. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W.
    Radiother Oncol; 2004 Mar 01; 70(3):261-4. PubMed ID: 15064010
    [Abstract] [Full Text] [Related]

  • 18. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):739-47. PubMed ID: 11849797
    [Abstract] [Full Text] [Related]

  • 19. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, Tesavibul C, Swangsilpa T, Khorprasert C, Shotelersuk K, Kongthanarat Y, Panichevaluk A, Chiewvit S, Pusuwan P, Aekmahachai M, Ratchadara S, Sirilipoche S, Saengsuda Y.
    J Med Assoc Thai; 2006 Dec 01; 89(12):2056-67. PubMed ID: 17214057
    [Abstract] [Full Text] [Related]

  • 20. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J.
    Cancer Invest; 2001 Dec 01; 19(2):107-13. PubMed ID: 11296615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.